All companies
Visit website
STEMBIOSYS
OperatingStemBioSys, Inc.
Healthcare · Technology · Founded 2012
The next evolution in cell culture
Post-money valuation ⓘ
$42.1M
As of Sep 2024 · from StemBioSys Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$71,834
Across 1 round since 2024
Latest share price
$3.00
StemBioSys Preferred Stock 1 offering price
Financials
FY2022–FY2024 · from SEC filings · hover any figure for its source$368K
$616K
2022
$550K
−$1.5M
2023
$278K
−$1.1M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
Income statement
Revenue
$367,734
$550,450
$278,147
Cost of goods sold
$0
$61,766
$66,899
Gross margin
100%
89%
76%
Net income
$616,327
-$1,537,261
-$1,110,753
Taxes paid
$0
$3,250
$2,686
Balance sheet
Cash
$50,372
$111,047
$1,218
Accounts receivable
$33,429
$21,212
$164,194
Total assets
$3,543,332
$2,938,750
$2,920,914
Short-term debt
$277,410
$1,586,281
$2,189,434
Long-term debt
$819,118
$405,497
$600,154
Total liabilities
$1,096,528
$1,991,778
$2,789,588
Other
Headcount
—
9
7
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$42.1M
post-money
StemBioSys Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $71.8K / $3MInvestors 41Post-money $42.1M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 1 of 2 annual reports (FY2024–FY2025)
41 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 12 filings on EDGARSource: ManualCIK 0001568861Share price $3.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.